Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis.

van Aalst M, Langedijk AC, Spijker R, de Bree GJ, Grobusch MP, Goorhuis A.

Vaccine. 2018 Sep 18;36(39):5832-5845. doi: 10.1016/j.vaccine.2018.07.039. Epub 2018 Aug 16. Review.

3.
4.

Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses.

Schaballie H, Wuyts G, Dillaerts D, Frans G, Moens L, Proesmans M, Vermeulen F, De Boeck K, Meyts I, Bossuyt X.

Clin Exp Immunol. 2016 Aug;185(2):180-9. doi: 10.1111/cei.12784. Epub 2016 May 20.

5.
6.

Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease.

Kantsø B, Halkjær SI, Thomsen OØ, Belard E, Gottschalck IB, Jørgensen CS, Krogfelt KA, Slotved HC, Ingels H, Petersen AM.

Vaccine. 2015 Oct 5;33(41):5464-5469. doi: 10.1016/j.vaccine.2015.08.011. Epub 2015 Aug 12.

PMID:
26275480
7.

Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: An evidence-informed and PRISMA compliant systematic review and meta-analysis.

Bragazzi NL, McGonagle D, Watad S, Adawi M, Mahroum N, Damiani G, Conic R, Bridgewood C, Mahagna H, Giacomelli L, Eggenhöffner R, Mahamid M, Pigatto PDM, Amital H, Watad A.

Autoimmun Rev. 2018 Nov 5. pii: S1568-9972(18)30264-7. doi: 10.1016/j.autrev.2018.08.002. [Epub ahead of print] Review.

PMID:
30408581
8.

Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine.

Gelinck LB, van der Bijl AE, Visser LG, Huizinga TW, van Hogezand RA, Rijkers GT, Kroon FP.

Vaccine. 2008 Jun 25;26(27-28):3528-33. doi: 10.1016/j.vaccine.2008.04.028. Epub 2008 May 2.

PMID:
18502006
9.

Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.

Lee KY, Tsai MS, Kuo KC, Tsai JC, Sun HY, Cheng AC, Chang SY, Lee CH, Hung CC.

Hum Vaccin Immunother. 2014;10(12):3700-10. doi: 10.4161/hv.32247. Review.

10.

Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.

Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2013 Aug 2;31(35):3594-602. doi: 10.1016/j.vaccine.2013.04.084. Epub 2013 May 18.

11.

Pneumococcal Carriage and Vaccine Coverage in Retirement Community Residents.

Becker-Dreps S, Kistler CE, Ward K, Killeya-Jones LA, Better OM, Weber DJ, Zimmerman S, Nicholson BP, Woods CW, Sloane P.

J Am Geriatr Soc. 2015 Oct;63(10):2094-8. doi: 10.1111/jgs.13651. Epub 2015 Oct 12.

PMID:
26456473
12.

Streptococcus pneumoniae Transmission Is Blocked by Type-Specific Immunity in an Infant Mouse Model.

Zangari T, Wang Y, Weiser JN.

MBio. 2017 Mar 14;8(2). pii: e00188-17. doi: 10.1128/mBio.00188-17.

13.

The ABC of pneumococcal infections and vaccination in patients with chronic kidney disease.

Vandecasteele SJ, Ombelet S, Blumental S, Peetermans WE.

Clin Kidney J. 2015 Jun;8(3):318-24. doi: 10.1093/ckj/sfv030. Epub 2015 May 7.

14.

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.

Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, Gomez-Reino J, Soma K, Mebus C, Wilkinson B, Hodge J, Fan H, Wang T, Bingham CO 3rd.

Ann Rheum Dis. 2016 Apr;75(4):687-95. doi: 10.1136/annrheumdis-2014-207191. Epub 2015 Mar 20.

15.

[Vaccinal Prevention of Lower Respiratory Tract Pneumococcal Disease in Adults Without Immunosuppression.]

Guchev IA.

Antibiot Khimioter. 2016;61(7-8):48-57. Review. Russian.

PMID:
29533560
16.

Impact of Pneumococcal Conjugate Vaccine Administration in Pediatric Older Age Groups in Low and Middle Income Countries: A Systematic Review.

Bonner K, Welch E, Elder K, Cohn J.

PLoS One. 2015 Sep 2;10(8):e0135270. doi: 10.1371/journal.pone.0135270. eCollection 2015.

17.

Pneumococcal polysaccharide vaccination administered early after neurotrauma or neurosurgery.

Hedberg AL, Pauksens K, Enblad P, Söderberg J, Johansson B, Käyhty H, Sjölin J.

Vaccine. 2017 Feb 7;35(6):909-915. doi: 10.1016/j.vaccine.2016.12.065. Epub 2017 Jan 6.

PMID:
28069358
18.

Evaluation of antibody levels over 3 years after 23-valent pneumococcal polysaccharide vaccination in patients with pulmonary diseases receiving steroids and immunosuppressive agents.

Akamatsu T, Inui N, Kusagaya H, Nakamura Y, Suda T, Chida K.

Clin Biochem. 2015 Feb;48(3):125-9. doi: 10.1016/j.clinbiochem.2014.11.005. Epub 2014 Nov 13.

PMID:
25448031
19.

Differences in Homing Potentials of Streptococcus pneumoniae-Specific Plasmablasts in Pneumococcal Pneumonia and After Pneumococcal Polysaccharide and Pneumococcal Conjugate Vaccinations.

Palkola NV, Pakkanen SH, Kantele JM, Pakarinen L, Puohiniemi R, Kantele A.

J Infect Dis. 2015 Oct 15;212(8):1279-87. doi: 10.1093/infdis/jiv208. Epub 2015 Apr 2.

20.

Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.

Sohn HS, Suh DC, Jang E, Kwon JW.

J Manag Care Pharm. 2010 Jan-Feb;16(1):32-45.

Supplemental Content

Support Center